Ectopic secretion of corticotropin (ACTH) by a tumour is most likely to respond to somatostatin analogues if hypercortisolaemia has not yet developed.
References
1.
BurrellL., GrayC.E., ThomsonJ.A.Failure of somatostain analogue SMS 201–995 to control Cushing's syndrome due to ectopic release of ACTH from a bronchial carcinoid.Scott Med J1989; 34: 553–4
2.
ZhangC.Y., YokogoshiY., YoshimotoK., Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103.Biochem Biophys Res Commun1995; 210: 805–15
3.
GreenmanY., MelmedS.Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumours.J Clin Endocrinol Metab1994; 78: 398–403
4.
HoflandL.J., LambertsS.W.Somatostatin receptors in pituitary function, diagnosis and therapy.Front Horm Res2004; 32: 235–52
5.
StallaG.K., BrockmeierS.J., RennerU., Octreotide exerts different effects in vivo and in vitro in Cushing's disease.Eur J Endocrinol1994; 130: 125–31
